Frontlight ResearchEarly access
SuspendedNo phase
Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital
Key facts
- Who runs it
- Tenwek Hospital
- Where
- Kenya1 site in 1 countryChoose a country to see its locations
- Trial code
- Status
- Suspended
- People taking part
- 75 people, planned
- Started
- Jun 2013
- Ended
- Jul 2024
- Type of study
- Interventional
- Treatments tested
- Endoscopic Mucosal Resection (EMR)
- Radiofrequency ablation
- Record updated
- 11 December 2023
- Why it stopped
- Medtronic owns Covidien \& closed study 11/18/15. Will reapply through Medtronic.
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (24)Hide the full registry criteria
Who can take part
- Participant is 18-85 years of age, inclusive
- Participant has had a prior endoscopy with Lugol's chromoendoscopy demonstrating an unstained lesion (USL) of at least 5 mm which on biopsy contained moderate grade dysplasia (MGD), high grade dysplasia (HGD), or esophageal squamous cell cancer (ESCC) of flat mucosa limited to the lamina propria, with no evidence of invasion
- The maximum allowable linear length of USL-bearing esophagus is 20 cm
- No more than 14 continuous linear cm of esophagus require treatment for MGD, HGD, or ESCC
- For patients with ESCC, CT scan of chest and upper third of the abdomen shows no exclusionary findings for the trial, such as metastasis
- Participant is not pregnant and has no plans to become pregnant in the ensuing 12 months (confirmation of pregnancy status in women of child-bearing age and ability required prior to each endoscopy with urine or blood test, if subject believes she may be pregnant or has missed a menstrual period)
- Participant is eligible for treatment and follow-up endoscopy and biopsy as required by the protocol
- Participant is willing to provide written, informed consent to participate in this clinical study and understands the responsibilities of trial participation
Who cannot take part
- Any prior endoscopic resection
- Any previous ablative therapy within the esophagus (photodynamic therapy, multipolar electrical coagulation, argon plasma coagulation, laser treatment, or other) or any radiation therapy to the esophagus
- Any previous esophageal surgery, except fundoplication
- Participant is using aspirin, clopidogrel, or non-steroidal anti-inflammatory drugs that cannot be discontinued 7 days before and after therapeutic sessions
- Any history of ESCC of the esophagus, except for ESCC of flat mucosa limited to the lamina propria diagnosed within 12 months of study enrollment
- History of coagulopathy, or use of warfarin within the past month
- Participant has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to informed consent, post-treatment instructions, or follow-up guidelines
- Participant suffers from psychiatric or other illness deemed by the investigator as an inability to comply with protocol
- Report of uncontrolled coagulopathy with international normalized ratio (INR) > 2 or platelet count <75,000 platelets per µL (note: laboratory testing is not required for all subjects in this study)
- Participant has an implantable pacing device (examples; automatic implantable cardioverter/defibrillator, neurostimulator, cardiac pacemaker) and has not received clearance for enrollment in this study by the physician responsible for the pacing device
- Esophageal stricture preventing passage of a therapeutic endoscope
- Any esophageal dilation in the past 12 months
- In participants with ESCC, any evidence of nodal involvement or distant metastases
- Evidence of esophageal varices detected within last 6 months or at initial EMR/RFA procedure
- Evidence of eosinophilic esophagitis on endoscopy and/or histology
- Participant has life expectancy less than 2 years
Where is this trial?
It has locations in one country. Choose a country to see its locations.
What happens in this trial
What the trial wants to find out
Esophageal cancer is common in Kenya. The precursor of esophageal cancer is esophageal squamous dysplasia (ESD). In this study, persons known to have ESD will undergo endoscopic removal or ablation of ESD in order to prevent development of esophageal cancer.
The group in the trial
- Endoscopic treatmentTreatment being tested
Participants undergo upper GI endoscopy with endoscopic mucosal resection (EMR) and/or radiofrequency ablation (RFA) of esophageal squamous dysplasia (ESD). After initial therapy participants undergo repeat endoscopy every 3 months for a year, with re-biopsy and re-treatment of residual ESD as appropriate.
Treatment: Endoscopic Mucosal Resection (EMR) and Radiofrequency ablation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital (The EXPECT Trial) by Removal or Ablation of Esophageal Squamous Cell Dysplasia
- Record updated
- 11 December 2023